Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0RP2X
|
|||
| Drug Name |
L19-TNF
|
|||
| Drug Type |
Fusion protein
|
|||
| Indication | Soft tissue sarcoma [ICD-11: 2B57; ICD-9: 171] | Phase 3 | [1] | |
| Company |
Philogen
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04650984) A Phase III Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.